Table 1.
Demographics of treatment-naïve (A) and pre-treated (B) BC patients and major clinical-pathological features.
| Clinico-pathological features | Metastatic disease | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt. code | Age | Time between BC diagnosis and CTC collection (months) | BC stage at diagnosis | Histological features of the primary tumor | Bone | Lung | Liver | Brain | Other sites | # of metastases (≤5; >5) | |||
| A) Treatment-naїve patients | |||||||||||||
| 274 | 41 | 2 | IV |
Ductal, G3, Ki67 70% ER-, PgR-, Her2neu− |
+ | − | + | − | + | >5 | |||
| 337 | 49 | 11 | IV |
Ductal, G3, Ki67 54% ER+, PgR+, Her2neu− |
− | + | − | − | + | >5 | |||
| 372 | 53 | 1 | IV |
Lobular, G NA, Ki67 15% ER+, PgR−, Her2neu− |
+ | − | − | − | − | >5 | |||
| 382 | 73 | 2 | IV |
Ductal, G3, Ki67 40% ER+, PgR+, Her2neu− |
+ | − | − | − | − | >5 | |||
| 392 | 77 | 1 | IV |
Ductal, G2, Ki67 18% ER+, PgR+, Her2neu− |
− | + | − | − | + | >5 | |||
| 407 | 47 | 2 | IV |
Ductal, G2, Ki67 27% ER+, PgR+, Her2neu+ |
+ | + | − | − | − | >5 | |||
| 454 | 65 | 120 | III |
Lobular, G3, Ki67 8% ER+, PgR+, Her2neu− |
− | + | − | − | − | ≤5 | |||
| Clinico-pathological features | Metastatic disease | ||||||||||||
| Pt code | Age | Time between BC diagnosis and CTC collection (months) | BC stage at diagnosis | Histological features of the primary tumor | N. of treatment lines for metastatic disease | Previous treatment | Time since last systemic treatment | Bone | Lung | Liver | Brain | Other sites | # of metastases (≤5; >5) |
| B) Pre-treated patients | |||||||||||||
| 123 | 54 | 12 | III |
Ductal, G3, Ki67 50% ER+, PgR+, Her2neu− |
0 | HT (adjuvant) | 21 days | − | − | − | − | + | ≤5 |
| 242 | 44 | 132 | III |
Ductal, G3, Ki67 14% ER+, PgR−, Her2neu− |
8 | CHT, HT | 25 days | + | + | − | − | + | >5 |
| 253 | 69 | 260 | I |
Ductal, G1, Ki67 NA ER+, PgR+, Her2neu+ |
6 | CHT, HT, TT | 60 days | + | + | + | − | + | >5 |
| 279 | 49 | 23 | IV |
Ductal, G NA, Ki67 32% ER+, PgR+, Her2neu− |
1 | HT | 21 days | + | − | − | − | − | >5 |
| 335 | 69 | 130 | II |
Ductal, G2, Ki67 36% ER+, PgR+, Her2neu− |
2 | CHT, HT | 22 days | + | + | − | − | + | >5 |
| 371 | 56 | 180 | III |
Ductal, G2, Ki67 16% ER+, PgR+, Her2neu− |
1 | CHT, HT | 38 days | − | − | + | − | − | ≤5 |
| 399 | 61 | 36 | III |
Ductal, G3, Ki67 45% ER+, PgR+, Her2neu+ |
0 | CHT, HT, TT (adjuvant) | 28 days | − | − | − | + | − | ≤5 |
| 431 | 52 | 132 | III |
Ductal, G2, Ki67 22% ER+, PgR+, Her2neu− |
0 | HT (adjuvant) | 6 years | + | − | − | + | − | >5 |
| 458 | 55 | 60 | III |
Ductal, G3, Ki67 70% ER−, PgR−, Her2neu− |
1 | CHT | 7 months | + | + | + | − | + | >5 |
| 471 | 67 | 58 | III |
Ductal, G3, Ki67 25% ER+, PgR+, Her2neu− |
0 | CHT, HT (adjuvant) | 21 days | − | − | − | − | + | >5 |
Abbreviations: BC: breast cancer; NA: not available; ER: estrogen receptor; PgR: progesterone receptor; Her-2neu: human epidermal growth factor receptor 2; CHT: chemotherapy; HT: hormone treatment; TT: targeted therapy; +: yes; −: no; #: number.